Comparative Pharmacology
Head-to-head clinical analysis: PRISTIQ versus SAVELLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRISTIQ versus SAVELLA.
PRISTIQ vs SAVELLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desvenlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI). It binds to the serotonin transporter (SERT) and norepinephrine transporter (NET), inhibiting reuptake of serotonin and norepinephrine, thereby increasing their synaptic concentrations.
Selective serotonin and norepinephrine reuptake inhibitor (SNRI); also weakly inhibits dopamine reuptake. Binds to serotonin and norepinephrine transporters, increasing their extracellular concentrations.
50 mg orally once daily, with or without food; may increase by 50 mg every 7 days to a maximum of 100 mg once daily; maximum dose is 100 mg/day (some studies up to 400 mg/day but not recommended).
100 mg orally twice daily; may initiate at 50 mg twice daily and increase to 100 mg twice daily after 1 week.
None Documented
None Documented
Desvenlafaxine: ~11 hours (range 8-15 h); supports once-daily dosing
Approximately 11 hours for milnacipran (SAVELLA). In the context of twice-daily dosing, steady state is reached within 2-3 days.
Renal: 87% (45% desvenlafaxine unchanged, 42% as metabolites); biliary/fecal: minimal (<1%)
Renal excretion of unchanged drug and metabolites accounts for approximately 51-58% of the dose. Fecal excretion accounts for about 19-22%. The remainder is eliminated via other routes (e.g., oxidative metabolism and subsequent conjugation).
Category C
Category C
SNRI Antidepressant
SNRI Antidepressant